Real-world experience of JAK Inhibitors in eyebrow regrowth for alopecia areata: a retrospective single-center study

It details a retrospective single-center study evaluating the real-world efficacy of oral JAK inhibitors, including ritlecitinib, tofacitinib, and baricitinib, for eyebrow regrowth in 74 patients with moderate-to-severe alopecia areata. By employing a modified scoring system known as mBETA to quantify improvement, the researchers observed that eyebrow regrowth was consistently faster and more complete than scalp regrowth, with 72.6% of patients achieving significant restoration (mBETA80) by Week 36. The findings indicate that these JAK inhibitors share comparable success rates and an acceptable safety profile, supporting their utility and allowing for individualized treatment approaches based on patient needs and accessibility.